Pharma Companies Left Out of Trump’s Drug-Pricing Deals Look for Way In
Several pharmaceutical companies that were not included in recent drug-pricing negotiations linked to former President Donald Trump’s policy framework are now exploring ways to join future agreements, according to industry analysts and policy observers. The developments highlight ongoing shifts in U.S. prescription drug pricing policy and the growing pressure on drugmakers to align with federal … Read more